Eugene Kim

Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in <i>KRAS-</i>mutated non-small cell lung cancer with <i>STK11</i>, <i>KEAP1,</i> or <i>TP53</i> comutations: subgroup results from the phase III IMpower150 trial

Howard West, Mark L. McCleland, Federico Cappuzzo et al. · Journal for ImmunoTherapy of Cancer · 2022 · 139 citations · Full text

TRAF2 is an NF-κB-activating oncogene in epithelial cancers

Rhine R. Shen, Alicia Y. Zhou, Eugene Kim et al. · Oncogene · 2013 · 67 citations · Full text

The Novel Cytokine p43 Induces IL-12 Production in Macrophages via NF-κB Activation, Leading to Enhanced IFN-γ Production in CD4+ T Cells

Eugene Kim, Seung Hyun Kim, Sung‐Hoon Kim et al. · The Journal of Immunology · 2006 · 50 citations · Full text

Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study

Christopher R. Bolen, Magdalena Klánová, Marek Trněný et al. · Haematologica · 2019 · 46 citations · Full text

Cancer Pathology, Immunology, Pathology +21

Exposure to 4-tert-octylphenol, an environmentally persistent alkylphenol, enhances interleukin-4 production in T cells via NF-AT activation

Mi H. Lee, Eugene Kim, Tae S. Kim · Toxicology and Applied Pharmacology · 2004 · 37 citations

Inflammation, Cytokine, Anti-inflammatory +12